Volcon ePowersports Reports Annual 2022 Operational and Financial Results

Written by Customer Service on March 6, 2023. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, March 06, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, today reported its operational highlights and financial results for fiscal year 2022. Company Highlights: Through December 31, 2022 signed 151 dealers Delivered the first 2023 Volcon Brats to customers in December 2022 Have taken pre-orders for the Stag of more than $116 million if all orders are fulfilled1 Taken delivery of our first three Stag validation units in early 2023 that include our custom suspension parts in addition to the GM propulsion components Grunt EVO and Runt launch expected in the second quarter of 2023 We signed 7 new dealers in the fourth quarter of 2022. Jordan Davis, CEO notes “In the fourth quarter of 2022, we purposely slowed signing of...

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Written by Customer Service on March 6, 2023. Posted in Earnings Releases And Operating Results.

Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Financial Officer Biotech industry veteran Elizabeth Keiley appointed Executive Vice President and General Counsel HIGH POINT, N.C., March 06, 2023 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of Type 1 diabetes, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided an update on recent corporate developments. “We have made a great deal of progress since I joined vTv early in the second half of 2022,” said Paul Sekhri,...

Neovasc Shareholders Approve Acquisition by Shockwave Medical

Written by Customer Service on March 6, 2023. Posted in Mergers And Acquisitions.

VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical, Inc. (“Shockwave”) by way of a statutory plan of arrangement (the “Arrangement”) at the special meeting of Shareholders held today (the “Meeting”). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders of the Company (the “Shareholders”) present in person or represented by proxy at the Meeting, and (ii) 97.21%...

Element Reports Strong Fourth Quarter and Record Full-Year 2022 Results, Reaffirms 2023 Guidance

Written by Customer Service on March 6, 2023. Posted in Dividend Reports And Estimates.

Amounts in $CAD unless otherwise noted Element grew net revenue 16.2% to a record $1.1 billion and adjusted operating income 22.0% to a record $624.5 million in 2022 Element’s scalable operating platform underpinned pre-tax income margin expansion of 150 basis points to 48.5%, and operating margin expansion of 260 basis points to 55.2%, for the full-year 2022 Q4 EPS and adjusted EPS grew 3 cents and 6 cents from Q4 2021, to $0.24 and $0.27, respectively The Company generated $0.30 of free cash flow per share in the quarter — 1 cent more than in Q4 2021 — and $1.35 of free cash flow per share for the full-year 2022 — 30 cents or 28.6% more than in 2021 Element advanced its capital-lighter business model, growing Q4 services revenue 20.6% and syndication revenue 21.7% year-over-year, together enhancing ROE and pre-tax...

Progressive Announces Quarterly Common Share Dividend and Appointment of Calculation Agent for Preferred Shares

Written by Customer Service on March 6, 2023. Posted in Dividend Reports And Estimates.

MAYFIELD VILLAGE, OHIO, March 06, 2023 (GLOBE NEWSWIRE) — On March 3, 2023, the Board of Directors of The Progressive Corporation (NYSE:PGR) declared a $0.10 per common share dividend, payable April 14, 2023, to shareholders of record at the close of business on April 6, 2023 (ex-dividend date of April 5, 2023). In addition, on March 3, 2023, The Progressive Corporation appointed itself as calculation agent for its Series B Fixed-to-Floating Rate Cumulative Perpetual Serial Preferred Shares. The floating rate period for the Series B shares begins on March 15, 2023. About ProgressiveProgressive Insurance® makes it easy to understand, buy and use car insurance, home insurance, and other protection needs. Progressive offers choices so consumers can reach us however it’s most convenient for them — online at progressive.com, by...

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 6, 2023. Posted in Earnings Releases And Operating Results.

NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today announced operating and financial results for its fourth quarter ended December 31, 2022. The contents of Calyxt’s announcement are included below: —Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4— —Current customer projects under development are on track— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell...

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

Written by Customer Service on March 6, 2023. Posted in Earnings Releases And Operating Results.

First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib (DAY101) in relapsed or progressive pLGG Additional data from FIREFLY-1 planned for presentation at a medical meeting in second quarter of 2023 New Drug Application (NDA) submission planned for tovorafenib (DAY101) in first half of 2023 BRISBANE, Calif., March 06, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth...

SEACOR Marine Announces Fourth Quarter 2022 Results

Written by Customer Service on March 6, 2023. Posted in Earnings Releases And Operating Results.

HOUSTON, March 06, 2023 (GLOBE NEWSWIRE) — SEACOR Marine Holdings Inc. (NYSE: SMHI) (the “Company” or “SEACOR Marine”), a leading provider of marine and support transportation services to offshore energy facilities worldwide, today announced results for its fourth quarter ended December 31, 2022. SEACOR Marine’s consolidated operating revenues for the fourth quarter of 2022 were $57.9 million, operating loss was $10.5 million, and direct vessel profit (“DVP”)(1) was $13.6 million. This compares to consolidated operating revenues of $48.0 million, operating loss of $14.7 million, and DVP of $12.9 million in the fourth quarter of 2021, and consolidated operating revenues of $59.8 million, operating loss of $10.9 million, and DVP of $15.8 million in the third quarter of 2022. Notable fourth quarter items include: Extended the maturity...

NCS Multistage Holdings, Inc. Announces Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 6, 2023. Posted in Earnings Releases And Operating Results.

Fourth Quarter Results Total revenues of $40.2 million, an 11% year-over-year increase Net income of $2.0 million, compared to $1.7 million for the fourth quarter of 2021, a $0.3 million improvement resulting in earnings per diluted share of $0.81 Adjusted EBITDA of $6.4 million, slightly below the fourth quarter of 2021 $16.2 million in cash and $7.9 million of total debt as of December 31, 2022 Full Year Results Total revenues of $155.6 million, a 31% increase over the prior year Net loss of $(1.1) million, compared to a net loss of $(4.7) million in 2021, a $3.6 million improvement resulting in loss per diluted share of $(0.45) Adjusted EBITDA of $15.1 million, compared to $9.1 million in 2021, a $6.0 million improvement HOUSTON, March 06, 2023 (GLOBE NEWSWIRE) — NCS Multistage Holdings, Inc. (Nasdaq: NCSM) (the “Company,”...

NeoGames Announces Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 6, 2023. Posted in Earnings Releases And Operating Results.

– Fourth Quarter Revenues and Share of NPI Revenues Interest total $83.2 million, up 291% year-over-year – – Full Year Revenues and Share of NPI Revenues Interest was $210.2 million – – Initiates Full Year 2023 Revenue and Share of NPI Revenues Guidance representing 10.4% year-over-year growth at the midpoint on a like-for-like basis – LUXEMBOURG, March 06, 2023 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery and iGaming solutions, announced today financial results for the fourth quarter and year ended December 31, 2022. Moti Malul, Chief Executive Officer of NeoGames, said: “We are proud of the tremendous progress we made during 2022, further solidifying our iLottery leadership position in a continually expanding market. A record year...

Day: March 6, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice